Savara (SVRA): Binary Approval Bet Ahead of 08/22 PDUFA - High Risk, High Upside Trade
Savara is a clinical-stage rare-disease pharma with a single lead asset, MOLBREEVI (inhaled recombinant GM-CSF) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company received a Day 74 Letter and is carrying a PDUFA target action date of 08/22/2026. With a market cap near $1.11B and elevated short interest, this is a binary lon…